Lupin has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at company’s Aurangabad facility, India, and is expected to be launched shortly.
Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain. Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $14 million in the US (IQVIA MAT March 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
